| __timestamp | BioCryst Pharmaceuticals, Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 25434000 |
| Thursday, January 1, 2015 | 1896000 | 23783000 |
| Friday, January 1, 2016 | 2699000 | 29763000 |
| Sunday, January 1, 2017 | 1702000 | 12065000 |
| Monday, January 1, 2018 | 471000 | 5508000 |
| Tuesday, January 1, 2019 | 4101000 | 75173000 |
| Wednesday, January 1, 2020 | 1676000 | 81497000 |
| Friday, January 1, 2021 | 7264000 | 85731000 |
| Saturday, January 1, 2022 | 6594000 | 63572000 |
| Sunday, January 1, 2023 | 4661000 | 54922000 |
| Monday, January 1, 2024 | 41070000 |
Cracking the code
In the ever-evolving world of biotechnology, understanding the financial dynamics of companies is crucial. This chart provides a fascinating comparison of the cost of revenue between Mesoblast Limited and BioCryst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Mesoblast Limited consistently reported higher costs, peaking in 2021 with a staggering 85.7 million, while BioCryst Pharmaceuticals saw a more modest peak in the same year at 7.3 million. This disparity highlights Mesoblast's aggressive investment in its operations, which is nearly 12 times that of BioCryst in 2021. However, BioCryst's cost of revenue has shown a more stable trend, with a notable increase in 2021, suggesting strategic scaling. The data for 2024 is incomplete, leaving room for speculation on future trends. This financial narrative underscores the diverse strategies within the biotech sector, offering insights into each company's operational priorities.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Mesoblast Limited
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Biogen Inc. and Mesoblast Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Analyzing Cost of Revenue: Walgreens Boots Alliance, Inc. and Mesoblast Limited
Cost of Revenue: Key Insights for Jazz Pharmaceuticals plc and Mesoblast Limited
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs BioCryst Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Telix Pharmaceuticals Limited and Mesoblast Limited
Cost of Revenue Comparison: ADMA Biologics, Inc. vs Mesoblast Limited
Comparing Cost of Revenue Efficiency: Mesoblast Limited vs Iovance Biotherapeutics, Inc.